Lexaria Extends Material Transfer Agreement with Pharmaceutical Company for GLP-1 Drug Delivery Technology Evaluation

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement (MTA) with a pharmaceutical company (PharmaCO) originally signed on August 30, 2024, to evaluate Lexaria's DehydraTECH technology in pre-clinical settings. The extension, now through December 31, 2026, allows additional time for PharmaCO to receive and review Lexaria's 2026 research and development results related to GLP-1 drugs.

The extended agreement keeps the temporary exclusive license active and enables further strategic planning discussions with PharmaCO's human clinical and business development teams. This development underscores the potential of Lexaria's patented oral drug delivery platform in the rapidly growing GLP-1 market, which includes therapies for diabetes and obesity.

Over the past 12 months, Lexaria has advanced its GLP-1 development program with three key studies: Human Study #7, Animal Study #1, and Animal Study #2. These studies are designed to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria's technology. All studies are fully funded with existing corporate resources, and results are expected during Q3 and Q4 of 2026.

The extension of the MTA is significant because it indicates continued interest from a pharmaceutical partner in Lexaria's DehydraTECH technology, which has repeatedly shown the ability to increase bio-absorption, reduce side effects, and enhance drug delivery across the blood-brain barrier. Successful results from the ongoing studies could lead to broader licensing agreements or partnerships, potentially accelerating the development of more effective oral GLP-1 therapies.

Lexaria's DehydraTECH platform is protected by a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. The company operates a licensed in-house research laboratory and focuses on improving oral drug delivery for a variety of drugs.

Investors should note that forward-looking statements in this announcement involve risks and uncertainties, including the outcomes of research initiatives, regulatory approvals, and market conditions. The company has provided additional information on these risks in its public filings with the SEC.

For more details about Lexaria and its technology, visit www.lexariabioscience.com.